Project Grant R41AG097311
Award Date 9/20/25
Completion Date 9/19/26
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Institute on Aging (NIA) awarded a $1,783,700.00 Project Grant under the Aging Research program (CFDA 93.866) to the University of Illinois to develop novel blood-brain barrier permeable multimodal imaging agents for the diagnosis of neurodegenerative diseases, with a focus on Alzheimer's disease and related dementias. The 3-year grant aims to employ organic and inorganic chemical design principles to generate diagnostic agents capable of detecting protein aggregation,...
- This Project Grant award of $497,878 from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will fund a Phase 0 study to evaluate the in vivo characteristics of a myeloperoxidase (MPO)-targeting PET imaging agent (18F-EH301) in healthy volunteers and early Alzheimer's disease (AD) patients. The study aims to develop a PET imaging tool that can detect and track neuroinflammation, a key early event in the development of AD, by specifically targeting...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,588 to develop non-radioactive nanoprobes for magnetic resonance imaging (MRI) of tropomyosin receptor kinase B (TrkB) in Alzheimer's disease. The goal is to create new MRI-based imaging tools to detect reduced TrkB expression, which is linked to impaired neurogenesis, synaptic damage, and neuronal death in Alzheimer's. The award recipient, Exqor Technologies Inc., will work to create a...
- This $871,261 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to Cellsight Technologies, Inc., a woman-owned small business based in San Francisco. The grant funds a project to investigate the use of the PET imaging agent [18F]F-ARAG as a biomarker for detecting and quantifying T cell immunity in patients with Alzheimer's disease. The immediate goal is to characterize and validate [18F]F-ARAG as an imaging tool for...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This Project Grant award of $437,875 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund a 2-year research project at the University of California, San Diego to quantify neurovascular protein lifetimes in the central nervous system under healthy, aging, and Alzheimer's disease conditions. The key objectives are to generate a comprehensive atlas of neurovascular protein lifetimes and identify changes associated with aging and Alzheimer's disease. The project will...
- This federal Project Grant award, valued at $782,495.00 and provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop a novel positron emission tomography (PET) ligand that can selectively image the enzyme poly(ADP-ribose) polymerase-1 (PARP1) in the living human brain. PARP1 dysregulation has been implicated in Alzheimer's disease and other neurodegenerative disorders, but there are currently no successful examples of imaging PARP1 in the human brain. The...
- The National Institute on Aging (NIA) awarded a $1,459,072 project grant to the J. David Gladstone Institutes under the Aging Research Federal Grant Program (CFDA 93.866) to monitor and manipulate inhibitory interneuron cell populations in mouse models of Alzheimer's disease. The 2-year project aims to use dual cell-type-specific enhancer-associated adeno-associated viruses (enhancer-AAVs) to independently monitor and control parvalbumin (PVALB) and somatostatin (SST) inhibitory interneurons...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Translucence Biosystems, Inc. a $1,025,651 Project Grant to develop and qualify a Vasculature Subtraction Parenchymal Quantification (VSPQ) workflow. The VSPQ workflow aims to enhance Translucence Biosystems' proprietary 3D brain imaging and analysis platform to precisely measure the distribution of antibody-based therapeutics within the brain parenchyma, addressing a key technological...